Langlui's Big Board and Options Plays

[langlui]

a few movers 9-17

Read more: http://www.briefing.com/Platinum/InDepth/InPlay.htm#ixzz2fAqoellI
Read more: http://www.briefing.com/Platinum/InDepth/InPlay.htm#ixzz2fAo1SSrU

13:42 CRME Cardiome Pharma announces commercialization agreement with Tzamal Medical Group for Brivaness in Israel (2.51 +0.09)
Co announced that its subsidiary, Cardiome Development AG, has entered into an agreement with Tzamal Medical to sell and distribute BRINAVESS (vernakalant intravenous) exclusively in Israel. Under the terms of the agreement, Tzamal Medical has agreed to specific annual commercial goals for BRINAVESS. Financial details of the agreement have not been disclosed.
11:11 SUMRX Sector Summary: The Healthcare sector (-0.27%) is trading slightly lower today, underperforming the S&P 500 (+0.34%)
General Commentary: Repros Therapeutics (RPRX) is up over 25% this morning. The company reported topline results from both the second pivotal efficacy study as well as the 6 month safety study of Androxal in the treatment of men with secondary hypogonadism. For study ZA-302, the pivotal efficacy study, results were almost identical to the previously reported study ZA-301. Both co-primary endpoints were met in each of the Androxal pivotal efficacy studies with respect to T normalization and sperm function conducted under a Special Protocol Assessment (SPA). For study ZA-300, the safety study, Androxal was generally well tolerated. Joseph Podolski, President and CEO noted, "We are encouraged by these outcomes. Our NDA filing remains on track for mid-2014. We believe we have the organization to successfully complete the required work and we have begun to prepare the necessary manufacturing documentation for the regulatory submission as well as having launch drug product available for an anticipated approval during 2015. The Company is in a strong financial position to maximize this unique Androxal opportunity."

Gainers on news:
Repros Therapeutics (RPRX +25.26%) Reported topline results from both the second pivotal efficacy study as well as the 6 month safety study of Androxal in the treatment of men with secondary hypogonadism; Androxal met both co-primary endpoints
KYTHERA Biopharmaceuticals (KYTH +24.81%) Announced positive ATX-101 top line Phase 3 trial results for th ereduction of submental fat
Agenus (AGEN +20.08%) Reported positive follow-on Phase 2 results for brain cancer vaccine in newly diagnosed patients
Decliners on news:
Omeros (OMER -11.33%) Reversal following strong gains seen yesterday due to positive analyst commentary
Gainers on earnings: No notable gainers on earnings

Decliners on earnings: No notable decliners on earnings

Upgrades/Downgrades:
Align Technologies (ALGN +3.33%) Target raised to $54 from $46 at Stifel
Volcano (VOLC +2.96%) Upgraded to Outperform from Market Perform at BMO Capital Markets
Auxilium Pharmaceuticals (AUXL +1.92%) Initiated with a Buy at Goldman
Cornerstone Therapeutics (CRTX -0.74%) Downgraded to Neutral from Buy at Ladenburg, target $9.50
Ironwood Pharmaceuticals (IRWD -1.91%) Initiated with a Sell at Goldman
Amarin (AMRN -2.05%) Initiated with a Neutral at Goldman